Press Releases

SAN DIEGO, Dec. 13, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today the Centers for Medicare and Medicaid Services (CMS) has published instructions for updates to the clinical laboratory fee schedule for 2012, including a revised reimbursement rate for the TearLab(r) Osmolarity Test, effective January 1, 2012. The payment code of 83861 that currently applies to the TearLab Osmolarity Test will be cross-walked or paired with code 84081. At current 2011 reimbursement rates, payment code 83861 would be reimbursed in every state by CMS at $23.25 per eye.

SAN DIEGO, Dec. 5, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that it is in receipt of a communication from the U.S. Food and Drug Administration ("FDA") indicating that, based on a supervisory review of the Company's appeal, the Agency has granted its petition for a waiver under CLlA for the TearLab(r) Osmolarity System. Upon the Company's submission of labeling acceptable to the Agency, the CLIA waiver will be issued.

SAN DIEGO, Nov. 22, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the 23rd Annual Piper Jaffray Healthcare Conference in New York, NY. The presentation is scheduled for Wednesday, November 30, 2011 at 8:30 AM Eastern Time.

SAN DIEGO, Nov. 10, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today reported its consolidated financial results for the third quarter ended September 30, 2011. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, Oct. 31, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q3 2011 financial results before the market opens on Thursday November 10, 2011.

SAN DIEGO, Sept. 19, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced that, today at the European Society of Cataract and Refractive Surgeons Annual Congress in Vienna, prominent LASIK surgeon, Dr. Eric Donnenfeld, presented data from a multi-site refractive surgery center study designed to determine how pre- and post-LASIK tear osmolarity levels relate to rates of Dry Eye Disease ("DED") and DED symptoms, if differences exist in patients who are pre-treated with ocular lubricants, and if pre-operative tear osmolarity levels relate to visual acuity outcomes.

SAN DIEGO, Sept. 7, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced the appointment of Richard Lee as the Company's EMEA Business Development Director. Mr. Lee will oversee sales, marketing, operations and customer service activities for Europe, the Middle East and Africa.

SAN DIEGO, Sept. 6, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced that Elias Vamvakas, the Company's Chief Executive Officer, will present an update on the Company's business at the Rodman & Renshaw 13th Annual Healthcare Conference on Monday, September 12, 2011 at 4:05 p.m. Eastern Time. The conference is being held at the The Waldorf-Astoria hotel in New York City.

SAN DIEGO, Aug. 23, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced that it has launched allaboutdryeye.com, a new consumer website and social media program focused on supporting the Company's Accredited Dry Eye Centers program in North America.

SAN DIEGO, Aug. 10, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today reported its consolidated financial results for the second quarter ended June 30, 2011. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, July 27, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q2 2011 financial results before the market opens on Wednesday, August 10, 2011.

SAN DIEGO, July 5, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced that it has closed its previously announced private placement of approximately 3.85 million units at a price of $1.82 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of US$1.86 per share. The Company has received total gross proceeds of approximately US$7 million.

SAN DIEGO, June 24, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced that it has entered into a definitive agreement with certain institutional investors and members of its Board of Directors in connection with a private placement of approximately 3.85 million units at a price of $1.82 per unit. Each unit shall consist of one share of common stock and a warrant to purchase one share of common stock at an exercise price of US$1.86 per share. Gross proceeds from the private placement will be US$7 million. The private placement is expected to close on or about June 29, 2011 and is subject to customary closing conditions, including acceptance and approval by the Toronto Stock Exchange.

SAN DIEGO, May 17, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today a unique new Individuelle Gesundheitsleistungen ("individual health benefits"), or IGel, code that applies to the TearLab(r) Osmolarity test in Germany. The new code is effective immediately.

SAN DIEGO, May 11, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today reported its consolidated financial results for the first quarter ended March 31, 2011. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, April 28, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2011 financial results for the first quarter before the market opens on Wednesday, May 11, 2011.

SAN DIEGO, April 26, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has been granted U.S Patent No. 7,905,134, entitled "Biomarker Normalization." This patent provides the company with broad and blocking intellectual property regarding the ability to compensate for first order dynamics in the eye, which is fundamental to accurate tear biomarker analysis, whether involving proteins, genes, or small molecules.

SAN DIEGO, March 28, 2011 -- TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter and the year ended December 31, 2010. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, March 15, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2010 financial results for the fourth quarter and fiscal year before the market opens on Monday, March 28, 2011.

SAN DIEGO, March 4, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that it is in receipt of a communication from the U.S. Food and Drug Administration ("FDA") indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab(tm) Osmolarity System.

SAN DIEGO, Jan. 11, 2011 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") and COLA, a private, non-profit clinical laboratory education, consultation and accreditation organization, announced today that they have partnered to help make the TearLab(tm) Osmolarity System available in the U.S. at the point-of-care.

SAN DIEGO, Nov. 11, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended September 30, 2010. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, Nov. 3, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2010 financial results for the third quarter before the market opens on Thursday, November 11, 2010.

SAN DIEGO, Oct. 19, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) announced today that, further to its press release of October 8, 2010, a unique new Current Procedural Terminology ("CPT") code that will apply to the TearLab(r) Osmolarity test has now been published by the American Medical Association ("AMA"). The new code will become effective January 1, 2011.

SAN DIEGO, Oct. 13, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has been granted U.S. Patent No. 7,810,380, entitled "Systems and methods for collecting tear film and measuring tear film osmolarity." This patent provides the company with broad and blocking intellectual property regarding the measurement of genetic and protein biomarkers within the tear film.

SAN DIEGO, Oct. 8, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) announced today that the Committee for Medicare and Medicaid Services (CMS) has published their recommended payment determination for new test codes, which includes a proposed reimbursement rate for the TearLab Osmolarity Test, effective January 2011. The new Current Procedural Terminology (CPT) code that will apply to the TearLab Osmolarity test will be reimbursed by CMS at $24.01 per eye (National Limit). The actual CPT code will be published by the American Medical Association in December 2010.

SAN DIEGO, Aug. 31, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has entered into a cooperative marketing agreement with Abbott Medical Optics Inc.'s subsidiary, AMO Canada Company ("AMO Canada"). Under the agreement, AMO Canada's sales force will directly sell the TearLab(tm) Osmolarity System in Canada while TearLab will help promote AMO Canada's products for the relief of dry eye symptoms, including Blink(r) Moisturizing Eye Drops. Financial terms were not disclosed.

Dry Eye Disease ("DED") is a common condition affecting approximately 100 million people worldwide. In its mild to moderate forms, it can reduce the quality of vision and the ability to go about daily activities. In its more severe forms, DED can lead to permanent loss of vision. According to numerous peer-reviewed studies, Tear Osmolarity is the single best test for the diagnosis of DED.

The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of DED in conjunction with other methods of clinical evaluation. Using a novel lab-on-a-chip approach, the TearLab System requires less than 50 nL (nanoliters) of tear fluid and displays quantitative osmolarity results in less than 30 seconds. By requiring such a small amount of tears, the TearLab System eliminates the challenges that previously prevented point-of-care osmolarity testing. In addition, it is simple enough to be operated by a technician, greatly improving patient throughput either in an office or center setting.

"We are proud to be working with a world-leading organization like AMO and are confident that, with their support, sales traction of the TearLab Osmolarity System will continue to build in Canada," said Elias Vamvakas, TearLab's Chief Executive Officer.

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab(tm) Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab(tm) Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

SAN DIEGO, Aug. 30, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced today the resignation of board member Thomas N. Davidson, 70, as per his planned retirement. The Company also announced that Brock J. Wright, MD, FRCPC has been appointed to its Board of Directors effective immediately.

SAN DIEGO, Aug. 12, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended June 30, 2010. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, Aug. 3, 2010 -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its financial results for the second quarter and six months ended June 30, 2010 before the market opens on Thursday, August 12, 2010.

SAN DIEGO, May 21, 2010 -- OccuLogix, Inc. (Nasdaq:TEAR) (TSX:TLB) today announced that the Company has officially changed its corporate name to TearLab Corporation.

SAN DIEGO, May 11, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("Tearlab") (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended March 31, 2010. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, May 6, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) today announced today that a variety of paper and poster presentations given at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) highlighted tear film osmolarity as the preferred tool in the evaluation of patients suffering from Dry Eye Disease ("DED") and further validated TearLab's(tm) unique ability to accurately measure subtle changes in the condition of the ocular surface.

SAN DIEGO, May 4, 2010 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2010 financial results for the first quarter before the market opens on Tuesday, May 11, 2010.

SAN DIEGO, March 25, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB), today reported its consolidated financial results for the quarter and the year ended December 31, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, March 18, 2010 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2009 financial results for the fourth quarter and full year 2009 before the market opens on Thursday, March 25, 2010.

SAN DIEGO, March 16, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) announced today that Paul M. Karpecki, OD, FAAO has been appointed to its Board of Directors.

SAN DIEGO, March 15, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB), announced today that it has obtained commitments from several investors to purchase approximately 1,552,795 million shares of its common stock and warrants to purchase approximately 621,118 shares of its common stock for gross proceeds of approximately $5,000,000. The investors have agreed to purchase the shares and warrants for $3.22 per unit (each unit consisting of one share and a warrant to purchase 0.4 shares of common stock). The exercise price of the warrants will be $4.00 per share. The warrants will be exercisable at any time on or after the sixth-month anniversary of the closing date through and until the 18-month anniversary of the closing of the offering. The closing of the offering is expected to take place on March 18, 2010, subject to satisfaction of customary closing conditions. TearLab plans to use the proceeds from this financing for general corporate purposes. Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq:RODM), acted as the exclusive placement agent for TearLab. Greybrook Capital Inc. acted as TearLab's financial advisor in connection with the transaction.

SAN DIEGO, March 10, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB), announced today that TLCVision Corporation, North America's premier eye care services company, will be incorporating the TearLab(tm) Osmolarity System ("TearLab System") in eight of its U.S. refractive surgery centers to study Dry Eye Disease ("DED") symptoms as they relate to LASIK surgery.

SAN DIEGO, Feb. 25, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) announced today that a peer-reviewed article published in the current issue of Contact Lens & Anterior Eye has provided further validation of the TearLab's(tm) unique ability to accurately measure subtle changes in the condition of the ocular surface.

SAN DIEGO, Jan. 11, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) today announced the sale of 1,886,291 shares of its common stock for an aggregate of approximately $1,700,000. This is the maximum currently allowable by the rules of the NASDAQ Capital Market without stockholder approval.

SAN DIEGO, Dec. 8, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB), announced today that Health Canada has issued a Medical Device License for the TearLab Osmolarity System. TearLab is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED), in conjunction with other methods of clinical evaluation. The Health Canada license allows the company to immediately begin marketing the system in Canada.

SAN DIEGO, Nov. 12, 2009 -- OccuLogix, Inc., dba TearLab Corporation (TearLab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended September 30, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, Oct. 26, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) announced that Gary Foulks, MD, FACS, presented the poster, "Osmolarity as a Biomarker for Disease Severity in Mild to Moderate Dry Eye Disease," from the TearLab Osmolarity Core Validation Study today at the 2009 American Academy of Ophthalmology (AAO) and Pan American Ophthalmology (PAAO) joint meeting in San Francisco, California.

SAN DIEGO, Aug. 12, 2009 -- OccuLogix, Inc., dba TearLab Corporation (Tearlab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended June 30, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, July 16, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdsaq:TEAR)(TSX:TLB) (the "Company) today announced that it has entered into and closed an agreement with certain investors whereby the investors agreed to provide financing (the "Financing") to the Company through the purchase of convertible secured notes, in the aggregate amount of $1.55 million. The convertible secured notes (the "Notes") evidencing the Financing, mature on the second anniversary of their issuance ("the Maturity Date"), bear interest at a rate of 12% per annum and are convertible into shares of the Company's common stock upon the request of holders of 51% or more of the outstanding principal amount of the Notes at any time after August 31, 2009 and prior to the Maturity Date. The conversion price of the Notes (the "Discount Price") will be 80% of the volume weighted average price on the NASDAQ stock market for the ten trading days prior to August 31, 2009, provided that the Discount Price will not exceed $2.40 per share and will not be less than $0.25 per share. Any such conversion is limited to prevent the number of shares issued upon conversion of the Notes from exceeding 19.9% of the outstanding common stock of the Company, measured prior to the date of the Financing.

SAN DIEGO, June 12, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that its TearLab(tm) Osmolarity System has received a Silver 2009 Medical Design Excellence Award (MDEA).

SAN DIEGO, May 19, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) an ophthalmic, in-vitro diagnostics company, today announced FDA 510(k) clearance of its award winning TearLab Osmolarity System. The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED), in conjunction with other methods of clinical evaluation. The 510(k) clearance allows the Company to immediately begin market activities in the U.S. to clinical facilities categorized as high or moderate complex under the Clinical Laboratory Improvement Act of 1988 (CLIA '88).

SAN DIEGO, May 14, 2009 -- OccuLogix, Inc., dba TearLab Corporation (TearLab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended March 31, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, April 9, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that its TearLab Osmolarity System has received a 2009 Medical Design Excellence Award (MDEA).

SAN DIEGO, April 6, 2009 -- OccuLogix, Inc., dba TearLab Corporation (Tearlab) (Nasdaq:TEAR) (TSX:TLB), announced that its financial statements for the year ended December 31, 2008, filed with its Annual Report on Form 10-K on March 31, 2009, included an audit report of Ernst & Young LLP, its Independent Registered Public Accounting Firm, dated March 25, 2009, which contained a going concern qualification.

SAN DIEGO, March 26, 2009 -- OccuLogix, Inc., dba TearLab Corporation (Tearlab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter and the year ended December 31, 2008. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, March 16, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that Benjamin Sullivan, PhD, Chief Scientific Officer for the Company, is scheduled to present at the Cowen & Company 29th Annual Health Care Conference in Boston, Massachusetts. A live webcast of its presentation scheduled for Tuesday, March 17, 2009, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time), may be accessed via the Internet.

SAN DIEGO, March 11, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has initiated an international clinical study which is designed to demonstrate the efficacy of the TearLab(tm) Osmolarity System as a practical tool for the diagnosis and assessment of severity of Dry Eye Disease (DED) by measuring the osmolarity of tears. Osmolarity, simply stated, is a measure of the concentration of particles or solute per liter of solution.

SAN DIEGO, Feb. 5, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR)(TSX:TLB) has announced that it has changed its independent registered public accounting firm from Ernst & Young LLP (Canada) ("EY Canada") to Ernst & Young LLP (United States) ("EY United States") to act as its auditors, commensurate with moving its corporate headquarters from Canada to San Diego, California.

SAN DIEGO, Jan. 20, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that Anthony E. Altig has been appointed to its Board of Directors and will also serve as the chairman of the Audit Committee of the Board.